Bristol-Myers Squibb Company (NYSE:BMY) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday. Happy Friday. My name is Mohit Bansal. I'm one of the biotech and pharma analyst here at Wells Fargo. I'm joined by my colleague, Cerena Chen. She wrote all the questions, so she might as well ask them ...

PM Images Bristol-Myers Squibb (NYSE:BMY) fell to $39.35 in July, and since then, has appreciated by 26.56% to $49.80. Despite climbing more than 25% over the past 2 months, I still believe there is a tremendous amount of value left to be unlocked from shares BMY after their Q2 earnings provided some validation to my investment thesis. Shares of BMY still yield 4.8% and trade at less than 10 times next year's earnings. With rate cuts on the way and CME Group predicting that there is a 100% chance that the r ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $49.80, denoting a -0.32% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.3%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, added 0.25%.The biopharmaceutical company's stock has climbed by 7.44% in the past month, exceeding the Medical sector's gain of 4.56% and the S&P 500's gain of 3.42%.The upcoming earnings release of Bristol Myers Squibb will be of great intere ...

Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody. I’m Terence Flynn, the U.S. Biopharma Analyst here at Morgan Stanley. Before we get started for important disclosures, please see the Morg ...

Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody. I’m Terence Flynn, the U.S. Biopharma Analyst here at Morgan Stanley. Before we get started for important disclosures, please see the Morg ...

Rebounding growth could make shares of this leading drugmaker a big winner.Bristol Myers Squibb (BMY 0.46%) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the pharmaceutical giant have pressured the stock in recent years; it's currently down about 34% from its record high in 2022.The backdrop is concerning. But the good news is that the company's latest update signaled what could be the start of a long-a ...

No stock is perfect, but quality businesses can stand the test of time in your portfolio.While a full-fledged, prolonged stock market correction could impact shares across a range of industries, investors with capital on hand can find that these periods present fortuitous opportunities to put cash to work. If you have the risk appetite to invest right now, there are plenty of tried-and-true businesses that have stood the test of time and can do so in a long-term investor's portfolio.Large-cap stocks, which ...

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq added 1.13%.Shares of the biopharmaceutical company have appreciated by 3.22% over the course of the past month, underperforming the Medical sector's gain of 4.91% and outperforming the S&P 500's gain of 2.5%.The upcoming earnings release of Bristol Myers Squ ...

Key TakeawaysSeveral pharmaceutical stocks moved higher Wednesday, bucking downward pressure on the broader markets.An array of clinical trial results and regulatory decisions helped boost shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals.The pharma industry has underperformed in 2024 despite several companies making headlines with blockbuster weight-loss treatments. Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top perfo ...

Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.High-yield dividend stocks can be enticing, with several academic studies showing that stocks yielding above 3% tend to outperform most other asset classes when held for 20 years or longer. However, dividend yield isn't the most important metric to consider when evaluating stocks with cash or stock distributions.A recent report by Hartford Funds reveals a crucial insight: Dividend stocks with payout ratios below 7 ...